Definitive agreement sells out the 10mL SoloGard production capacity at Sharps' manufacturing site in the EU and drives expansion to support the project's growth in the future Sharps' portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter NEW YORK, July 25, 202 ...

Voting deadline is Friday, July 12, at 11:59 p.m. Eastern Time. In order to continue Sharps Technology's solid progress toward achieving its goals, I want to share with you the importance of the three proposals on the shareholder ballot and ask you to take a few moments to vote to approve them. Our leadership team is moving forward aggressively to increase the Company's valuation through strategic partnerships and customer opportunities that will drive the need to expand our manufacturing capacity in Europe ...

Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company's continued growth. NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Executive Officer. Dear Fellow Shareholders: Up for vote on the ballot are the following three p ...

"This shipment is a great step in building strategic partnerships within the entire Latin American distribution network and supporting region-wide efforts to improve medical safety and healthcare outcomes," comments Robert Hayes, Sharps Technology CEO. "While implementing wide-scale change can be challenging, based on our studies we are confident that once healthcare practitioners use Securegard syringes, they will want to continue to use them, leading to long-term purchase orders and deliveries." NEW YORK, ...

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, has made the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders were placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant ...

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. Additionally, a five-year, $200 million sales agreement with Nephron will see Sharps' next-generation copolymer prefillable syringes manufactured at the South Carolina plant and 10mL SoloGard polypropylene syringes fro ...

Current Asset Purchase Agreement closing timeline is on track for expected prefillable syringe product shipments to begin by Q2 of 2025. Braden Miller, Sharps Director of Product Development, commented, "Sharps has developed an exciting alternative to glass syringes through the use of molded inert polymers, offering a high-quality solution compared to traditional glass syringe systems." Sharps prefillable polymer syringes have many of the same characteristics as traditional glass designs to support long ter ...

Signed PO secures first 12 months of syringe product orders against Sharps and Nephron's five-year, $200 million Syringe Sales Agreement. Braden Miller, Sharps Director of Product Development, commented, "Sharps has developed an exciting alternative to glass syringes through the use of molded inert polymers, offering a high-quality solution compared to traditional glass syringe systems." Sharps prefillable polymer syringes have many of the same characteristics as traditional glass designs to support long te ...

InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of $1 million into third-party escrow account. Closing on the Asset Purchase and the Syringe Sales Agreement, for product orders totaling over $200 million for the first five years of operation, is expected within the next 60 days. Based on the most likely timeframe, product shipments from the SC facility are planned to begin by Q2 of 2025. NEW YORK, June 05, 2024 (GLOBE NE ...

Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. Signed Syringe Sales Agreement will secure product orders totaling over $200 million for the first five years of operation. Sharps is negotiating additional pharma-segment purchase commitments for orders over the next three years, with shipments expected to begin by Q2 of 2025. Demand for Sharps products is increasing due to recent FDA warni ...